Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; 1 of the 24 sources its claims cite were checked for support.
Abstract
Epigenetic modifiers have fundamental roles in defining unique cellular identity through the establishment and maintenance of lineage-specific chromatin and methylation status. Several DNA modifications such as 5-hydroxymethylcytosine (5hmC) are catalysed by the ten eleven translocation (Tet) methylcytosine dioxygenase family members, and the roles of Tet proteins in regulating chromatin architecture and gene transcription independently of DNA methylation have been gradually uncovered. However, the regulation of immunity and inflammation by Tet proteins independent of their role in modulating DNA methylation remains largely unknown. Here we show that Tet2 selectively mediates active repression of interleukin-6 (IL-6) transcription during inflammation resolution in innate myeloid cells, including dendritic cells and macrophages. Loss of Tet2 resulted in the upregulation of several inflammatory mediators, including IL-6, at late phase during the response to lipopolysaccharide challenge. Tet2-deficient mice were more susceptible to endotoxin shock and dextran-sulfate-sodium-induced colitis, displaying a more severe inflammatory phenotype and increased IL-6 production compared to wild-type mice. IκBζ, an IL-6-specific transcription factor, mediated specific targeting of Tet2 to the Il6 promoter, further indicating opposite regulatory roles of IκBζ at initial and resolution phases of inflammation. For the repression mechanism, independent of DNA methylation and hydroxymethylation, Tet2 recruited Hdac2 and repressed transcription of Il6 via histone deacetylation. We provide mechanistic evidence for the gene-specific transcription repression activity of Tet2 via histone deacetylation and for the prevention of constant transcription activation at the chromatin level for resolving inflammation.
Overview
CoChat Summary
TL;DR
Tet2 actively represses Il6 transcription during the late phase of LPS-driven inflammation in myeloid cells by recruiting Hdac2 to the Il6 promoter, independent of DNA methylation. Tet2 loss prolongs IL-6 production and worsens endotoxin shock and DSS-induced colitis in mice.
Key findings
- In Tet2-deficient or Tet2-silenced dendritic cells and macrophages, the early LPS-induced rise in Il6 mRNA before 4 h was largely unchanged, but after 8 h Il6 mRNA remained elevated while control cells declined; IL-6 protein also increased, whereas Tnfa levels were similar. Tet3 silencing barely affected Il6.
- Tet2-deficient mice produced more IL-6 after systemic LPS, especially late, and showed worse lung tissue damage; in DSS colitis they had greater weight loss, higher IL-6, more inflammatory cell infiltration, and mucosal disruption. In Tet2-deficient BMDC, 22 genes were downregulated and 13 upregulated; 12 of the upregulated genes were TLR-induced, including Il6.
- IκBζ interacted with Tet2 and was required for Tet2 binding to the Il6 promoter at late LPS phase. IκBζ overexpression increased Il6 early but reduced it late, and Tet2 loss impaired this late repression.
- Tet2 associated with Hdac1/Hdac2 through its core-DSBH domain. Hdac2 binding at the Il6 promoter fell early and returned late; Hdac2 knockdown increased Il6 transcription and histone acetylation at 10 h, with Hdac1 compensation by 12 h. Catalytically mutant Tet2 still repressed Il6, and Tet2 loss reduced Hdac2 binding and late histone deacetylation.
Methods
- Mouse models included C57BL/6, Tet2fl/fl, Tet2-deficient, and Lyz2-Cre myeloid-specific Tet2-deficient mice; human monocytes came from healthy donors. Cells studied included BMDC, BMM, peritoneal macrophages, and splenic T, B, and NK cells, with LPS at 100 ng/ml; in vivo models were endotoxin shock and DSS colitis.
- Assays included RNA-seq, qPCR, ELISA, immunoblot, immunoprecipitation, co-IP with LC-MS/MS, ChIP and re-ChIP, luciferase reporters, siRNA knockdown, overexpression, and a GAL4-based recruitment assay.
- Statistics used unpaired Student’s t-tests with *P < 0.05 and P < 0.01; error bars were s.e.m. or s.d.; data were from triplicate technical or biological replicates and representative of three independent experiments.
Limitations
- The paper states that animal studies did not randomize by weight or sex and did not use blinding, and that sample size was not predetermined by a statistical method. It also states that HEK293T cells were not authenticated or tested for mycoplasma.
- Evident from the text: Hdac2 knockdown effects were transient because Hdac1 appeared to compensate by 12 h, complicating conclusions about Hdac2-specific repression.
- Evident from the text: many mechanistic experiments relied on overexpression or siRNA in HEK293T or primary cells, and the in vivo work used two inflammatory models; the authors note that additional Tet2-repressed mediators may exist in tissue-resident immune cells.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
1 Valid · 0 Not valid · 16 Not checked · 86 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“MS-275 strongly inhibits Hdac1/2 over Hdac3 (ref. 19)”
§ Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 > Abstract
What the sources say
- Supportedcites [19] Inoue, S., Mai, A., Dyer, M. J. & Cohen, G. M. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 66, 6785–6792 (2006) source
In the Results section 'Expression of HDACs in CLL cells and various cell lines', our copy reports that MS-275 (1-2.5 micromol/L) inhibited HDAC1 and HDAC2 activities by ~50-70% whereas 1 micromol/L did not inhibit HDAC3 (~20% only at 2.5 micromol/L), and explicitly frames the experiment as confirming that 'MS-275 was selectively inhibiting HDAC1 and HDAC2 rather than HDAC3'. The same section also states MS-275 preferentially inhibits HDAC1 (IC50 ~0.3 micromol/L) versus HDAC3 (IC50 ~8 micromol/L), though that IC50 comparison is itself credited to ref. 32; the paper's own immunoprecipitation/activity data carry the claim. Thus the paraphrase 'strongly inhibits Hdac1/2 over Hdac3' matches what this source attributes to MS-275. (LLM, conf=0.86)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“overexpressed Tet2 recruited more endogenous Hdac2 to the Il6 promoter”
§ Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Attenuated histone deacetylation in Tet2-deficient cells was also observed at late phase during LPS response”
§ Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 > Abstract
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“loss of Tet2 caused higher expression of IFN-γ in activated CD8+ T cells”
§ Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Loss of Tet2 barely affects TLR4 signalling pathways”
§ Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 > Extended Data
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
45 more claims
Create a free account to see all 103 claims and to verify the 15 references still open.
- It may state two separate claims as one. 31
- Probably not a substantial claim. 28
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“mice deficient in Tet2 developed more severe inflammation in several tissues upon challenge with bacterial endotoxin”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [91]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“this effect on Il6 expression was independent of the catalytic function of Tet2”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [91]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“loss of TET2, an enzyme that catalyzes DNA demethylation, results in prolonged and high expression of proinflammatory cytokines, including IL-6 [180].”
From Transition from inflammation to proliferation: a critical step during wound healing (2016) · cites this paper as [180]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As CHIP-associated mutations are known to alter the development and function of myeloid cells”
From Clonal hematopoiesis is associated with protection from Alzheimer’s disease (2023) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These results contrast with findings in peripheral macrophages after intraperitoneal injection in vivo (Zhang et al., 2015).”
From TET2 Regulates the Neuroinflammatory Response in Microglia (2019) · cites this paper as Zhang et al., 2015
Experimental — accuracy not yet measured
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Cytokines in inflammatory bowel disease
Neurath, M. F. (2014) · Nature Reviews Immunology · doi:10.1038/nri3661 · Cited by 2,706
IL-6 as a keystone cytokine in health and disease
Hunter, C. A., & Jones, S. A. (2015) · Nature Immunology · doi:10.1038/ni.3153 · Cited by 2,511
Ito, S., D’Alessio, A. C., Taranova, O. V., Hong, K., Sowers, L. C., & Zhang, Y. (2010) · Nature · doi:10.1038/nature09303 · Cited by 2,373
TET enzymes, TDG and the dynamics of DNA demethylation
Kohli, R. M., & Zhang, Y. (2013) · Nature · doi:10.1038/nature12750 · Cited by 1,623
Suppression of inflammation by a synthetic histone mimic
Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.-W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010) · Nature · doi:10.1038/nature09589 · Cited by 1,563
Gene-specific control of inflammation by TLR-induced chromatin modifications
Foster, S. L., Hargreaves, D. C., & Medzhitov, R. (2007) · Nature · doi:10.1038/nature05836 · Cited by 1,344
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation
Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.001 · Cited by 1,339
Self-citationImpaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2
Ko, M., Huang, Y., Jankowska, A. M., Pape, U. J., Tahiliani, M., Bandukwala, H. S., An, J., Lamperti, E. D., Koh, K. P., Ganetzky, R., et al. (2010) · Nature · doi:10.1038/nature09586 · Cited by 1,213
Distinct Effects of T-bet in T H 1 Lineage Commitment and IFN-γ Production in CD4 and CD8 T Cells
Szabo, S. J., Sullivan, B. M., Stemmann, C., Satoskar, A. R., Sleckman, B. P., & Glimcher, L. H. (2002) · Science · doi:10.1126/science.1065543 · Cited by 1,172
Cited by
Items 301–400 of 797
Genomic Aging, Clonal Hematopoiesis, and Cardiovascular Disease
Natarajan, P. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318181 · Cited by 36
Mitchell, K., & Steidl, U. G. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a036251 · Cited by 40
“Loss of function mutations in Tet2 therefore derepressed these signals and contributed to an inflammatory environment, which in the leukemia setting could promote disease progression (Zhang et al. 2015; Fuster et al. 2017; Jaiswal et al. 2017).”
BackgroundCheng, Z., Zhou, Y., Xiong, X., Li, L., Chen, Z., Wu, F., Dong, R., Liu, Q., Yan, Z., Jiang, S., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155283 · Cited by 35
The role of hypernitrosylation in the pathogenesis and pathophysiology of neuroprogressive diseases
Morris, G., Walder, K. R., Carvalho, A. F., Tye, S. J., Lucas, K., Berk, M., & Maes, M. H. J. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.07.017 · Cited by 33
“HDAC-2 suppresses the expression of a myriad of inflammatory genes, notably interleukin (IL)6 and hence plays a key role in the termination of the immune response (Barnes, 2009; Volmar and Wahlestedt, 2015; Zhang et al., 2015).”
Clonal hematopoiesis and VEXAS syndrome: survival of the fittest clones?
Kusne, Y. N., Fernandez, J. A., & Patnaik, M. M. (2021) · Seminars in Hematology · doi:10.1053/j.seminhematol.2021.10.004 · Cited by 35
Emergency myelopoiesis in solid cancers
Aliazis, K., Yenyuwadee, S., Phikulsod, P., & Boussiotis, V. A. (2024) · British Journal of Haematology · doi:10.1111/bjh.19656 · Cited by 36
“36 Pro-inflammatory cytokines are required to maintain the appropriate number of HSC, to promote their proliferation and differentiation, not only in response to stress but also under homeostatic conditions.”
Therapy-induced microenvironmental changes in cancer
Ma, Y., Yang, H., Pitt, J. M., Kroemer, G., & Zitvogel, L. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1401-8 · Cited by 35
“eloid cells [54], whereas TET2 dysfunction is correlated with poor clinical outcome of hematopoietic malignancy [55, 56].”
BackgroundAyachi, S., Buscarlet, M., & Busque, L. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.01.008 · Cited by 33
McGettrick, A. F., & O'Neill, L. A. J. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102268 · Cited by 33
Tong, W.-H., Maio, N., Zhang, D., Palmieri, E. M., Ollivierre, H., Ghosh, M. C., McVicar, D. W., & Rouault, T. A. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018015669 · Cited by 37
“Recent studies have suggested that histone deacetylation is an important mechanism in the deactivation of inflammatory genes.(56,57) Furthermore, we showed that silencing of Fe-S cluster biogenesis could increase MEC17 levels and induce tubulin acetylation.”
BackgroundTET protein inhibitors: Potential and limitations
Kaplánek, R., Kejík, Z., Hajduch, J., Veselá, K., Kučnirová, K., Skaličková, M., Venhauerova, A., Hosnedlová, B., Hromádka, R., Dytrych, P., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115324 · Cited by 38
Illuminating the Role of Vpr in HIV Infection of Myeloid Cells
Nodder, S. B., & Gummuluru, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01606 · Cited by 38
Clinico-Biological Features and Clonal Hematopoiesis in Patients with Severe COVID-19
Duployez, N., Demonchy, J., Berthon, C., Goutay, J., Caplan, M., Moreau, A.-S., Bignon, A. L., Marceau‐Renaut, A., Garrigue, D., Raczkiewicz, I., et al. (2020) · Cancers · doi:10.3390/cancers12071992 · Cited by 32
“Studies using murine models have also demonstrated that Dnmt3a- and Tet2-deficient animals were characterized by impaired production of type I interferon and increased IL-6 production, respectively, compared to wild-type mice [12,17].”
BackgroundTETology: Epigenetic Mastermind in Action
Seethy, A. A., Pethusamy, K., Chattopadhyay, I., Sah, R., Chopra, A., Dhar, R., & Karmakar, S. (2021) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-021-03537-5 · Cited by 31
Macrophage migration inhibitory factor is overproduced through EGR1 in TET2low resting monocytes
Pronier, E., Imanci, A., Selimoglu‐Buet, D., Badaoui, B., Itzykson, R., Roger, T., Jego, C., Naimo, A., Francillette, M., Breckler, M., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03057-w · Cited by 34
Byun, S., Lee, C. H., Jeong, H., Kim, H., Kwon, H. M., Park, S. H., Myung, K., An, J., & Ko, M. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2205626119 · Cited by 38
Epigenetic Reprogramming of the Inflammatory Response in Obesity and Type 2 Diabetes
Zatterale, F., Raciti, G. A., Prevenzano, I., Leone, A., Campitelli, M., Rosa, V. D., Bèguinot, F., & Parrillo, L. (2022) · Biomolecules · doi:10.3390/biom12070982 · Cited by 33
“HDAC3, for example, promotes M1 macrophage polarization by acting as an epigenomic brake in macrophage alternative activation [65], while HDAC2, recruited by Tet2, represses transcription of IL-6 via histone deacetylation, promoting a resolution of the inflammation [66].”
BackgroundLifelong partners: Gut microbiota-immune cell interactions from infancy to old age
Brown, J. A., Bashir, H., & Zeng, M. Y. (2025) · Mucosal Immunology · doi:10.1016/j.mucimm.2025.01.006 · Cited by 35
Wang, Q., Wang, C., Li, N., Liu, X., Ren, W., Wang, Q., & Cao, X. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.05.004 · Cited by 34
Self-citationAcetylation in Tumor Immune Evasion Regulation
Lu, J., He, X., Zhang, L., Zhang, R., & Li, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.771588 · Cited by 30
“…Ⅰ Gao et al. (2020) Melanoma ISG promoter deacetylates IFN-stimulated genes (ISG) promoter at H4K16 to enhances the infiltration of tumor lymphocytes Zhang et al. (2015) Macrophages c-Jun promoter repress the expression of c-Jun Fang et al. (2018) Wu et al. (2019) HDAC3 Melanoma Runx3 inhibits…”
BackgroundEpigenetics of Dendritic Cells in Tumor Immunology
Godoy‐Tena, G., & Ballestar, E. (2022) · Cancers · doi:10.3390/cancers14051179 · Cited by 31
“It has also been shown that TET2 represses the expression of the pro-inflammatory cytokine IL-6 by recruiting HDAC2 in order to resolve inflammation in innate myeloid cells [119].”
BackgroundRole of TET dioxygenases in the regulation of both normal and pathological hematopoiesis
Joshi, K., Zhang, L., Breslin, P., Kini, A. R., & Zhang, J. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02496-x · Cited by 33
“(Figure 1) In addition, through interacting with IκBζ or Egr1, Tet2 represses the production of inflammatory cytokines IL-6 and MIF in monocytes by recruiting histone deacetylases to their promotors [6].”
BackgroundThe Potential Biotherapeutic Targets of Contrast-Induced Acute Kidney Injury
Cheng, A. S., & Li, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098254 · Cited by 34
Self-citationThe lifelong natural history of clonal hematopoiesis and its links to myeloid neoplasia
Fabre, M. A., & Vassiliou, G. S. (2023) · Blood · doi:10.1182/blood.2023019964 · Cited by 34
Zhang, J., Zhao, K., Zhou, W., Kang, R., Wei, S., Shu, Y., Cheng, Y., Ku, Y., Mao, Y., Luo, H., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01778-4 · Cited by 33
“Accumulating evidences have demonstrated that TET2 was involved in the regulation of in fl ammation 31,32 and the homeostasis of immune system 33 through regulating IL-6 .”
BackgroundSelf-citationPNPO–PLP axis senses prolonged hypoxia in macrophages by regulating lysosomal activity
Sekine, H., Takeda, H., Takeda, N., Kishino, A., Anzawa, H., Isagawa, T., Ohta, N., Murakami, S., Iwaki, H., Kato, N., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01053-4 · Cited by 30
“Another role of TET2 has been reported to recruit HDAC for limiting deposition of acetylated histones at the Il6 locus in response to LPS 28 .”
Chu, Y., Zhao, Z., Sant, D., Zhu, G., Greenblatt, S. M., Liu, L., Wang, J., Cao, Z., Tho, J. C., Shi, C., et al. (2018) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2018.04.005 · Cited by 31
“Recent studies have revealed that Tet2 can exert its function through both catalytic activity-dependent and -independent fashions [29,44,45].”
BackgroundLi, L., Qiu, Y., Miao, M., Liu, Z., Li, W., Zhu, Y., & Wang, Q. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz282 · Cited by 32
Aging and leukemic evolution of hematopoietic stem cells under various stress conditions
Kurosawa, S., & Iwama, A. (2020) · Inflammation and Regeneration · doi:10.1186/s41232-020-00138-3 · Cited by 30
“Moreover, Tet2 recruits Hdac2 and represses the transcription of Il6 via histone deacetylation [98].”
BackgroundHuang, Z., Wei, P., Gan, L., Li, W., Zeng, T., Qin, C., Chen, Z., & Liu, G. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.11953 · Cited by 31
“HDAC2, a subtype of type I HDAC, is located in the nucleus and is primarily involved in inflam‐ matory inhibition (43,44).”
BackgroundEpigenetic‐modifying therapies: An emerging avenue for the treatment of inflammatory skin diseases
Yi, J. Z., & McGee, J. S. (2021) · Experimental Dermatology · doi:10.1111/exd.14334 · Cited by 34
Luo, S., Wu, R., Li, Q., & Zhang, G. (2022) · Journal of Immunology Research · doi:10.1155/2022/4053038 · Cited by 35
Wang, C., Li, X., Xue, B., Yu, C., Wang, L., Deng, R., Liu, H., Chen, Z., Zhang, Y., Fan, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34659-x · Cited by 30
Self-citationDNA Methylation: Basic Biology and Application to Traumatic Brain Injury
Mateen, B. A., Hill, C. S., Biddie, S. C., & Menon, D. K. (2017) · Journal of Neurotrauma · doi:10.1089/neu.2017.5007 · Cited by 32
“45 TET2 is thought to be important in resolving inflam-mation by suppressing IL-6, 34 which is known to be produced by macrophages/microglia.”
Hamilton, B. K., Rybicki, L. A., Hirsch, C. M., Przychodzen, B. P., Nazha, A., Gerds, A. T., Hanna, R., Kalaycio, M. E., Sekeres, M. A., Sobecks, R. M., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0444-1 · Cited by 30
Bedenbender, K., Scheller, N., Fischer, S., Leiting, S., Preissner, K. T., Schmeck, B., & Vollmeister, E. (2019) · The FASEB Journal · doi:10.1096/fj.201900451r · Cited by 32
“These findings are supported by the essential role of class I HDACs, especially HDAC2, in inflammation: in the context of LPS induced inflammation, HDAC2 has been observed to down-regulate expression of IL-6 by recruitment to its promoter and subsequent deacetylation of H4 and H3 in myeloid cells (66).”
BackgroundClonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms
Kjær, L. (2020) · Cancers · doi:10.3390/cancers12082100 · Cited by 32
“Although it was uncovered that loss of function mutations in TET2 induce pro-inflammatory processes [133,134], it nevertheless came as a surprise when NGS analysis of large cohorts discovered that ASXL1, TET2, and DNMT3A mutations doubled the risk for CVD, whereas the JAK2V617F mutation itself increased the risk 10-fo…”
BackgroundClonal Hematopoiesis in Hospitalized Elderly Patients With COVID‐19
Hameister, E., Stolz, S. M., Fuhrer, Y., Thienemann, F., Schaer, D. J., Nemeth, J., Schuepbach, R. A., Goede, J. S., Reinhart, S., Schmidt, A. E., et al. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000453 · Cited by 28
“Mechanistically, it has been shown that loss-of-function mutations in the epigenetic modifiers DNMT3A and TET2 lead to de-repression of genes for inflammatory mediators such as interleukin-1 (IL-1) and interleukin-6 (IL-6).(11,12) Thus, monocytes and macrophages with mutations in DNMT3A and TET2 acquire a strong proin…”
BackgroundVitamin C: A stem cell promoter in cancer metastasis and immunotherapy
Fu, J., Wu, Z., Liu, J., & Wu, T. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110588 · Cited by 32
Self-citationInteraction Between microRNA and DNA Methylation in Atherosclerosis
Tao, J., Xia, L., Cai, Z., Liang, L., Chen, Y., Meng, J., & Zuo, W. (2020) · DNA and Cell Biology · doi:10.1089/dna.2020.6138 · Cited by 28
“Mean-while, TET2 regulates VSMC phenotype (Liu et al. , 2013) and inflammatory cytokinesis transcription (Zhang et al. , 2015) and it has a protective role in AS (Liu et al. , 2018b).”
Single-nucleotide methylation specifically represses type I interferon in antiviral innate immunity
Gao, Z., Li, W., Mao, X.-T., Huang, T., Wang, H., Li, Y., Liu, B.-Q., Zhong, J.-Y., Chai, R., Jin, J., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20201798 · Cited by 34
Association of Somatic TET2 Mutations With Giant Cell Arteritis
Robinette, M. L., Weeks, L. D., Kramer, R. J., Agrawal, M., Gibson, C. J., Yu, Z., Sekar, A., Mehta, A., Niroula, A., Brown, J. T., et al. (2023) · Arthritis & Rheumatology · doi:10.1002/art.42738 · Cited by 30
Global profiling of protein lactylation in microglia in experimental high-altitude cerebral edema
Jiang, X., Gao, J., Fei, X., Geng, Y., Yue, X., Shi, Z., Cheng, X., Zhao, T., Fan, M., Wu, H., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01748-x · Cited by 35
“For example, HDAC2 is recruited by Tet2 and participates in the inhibition of IL-6 gene expression [42].”
BackgroundHerbrich, S., Chaib, M., Anandhan, S., Andrewes, S. W., Nagarajan, A., Guan, B., Gandhi, N., Gilliam, J., Radovich, M., & Sharma, P. (2026) · Cancer Cell · doi:10.1016/j.ccell.2025.09.011 · Cited by 30
Wang, X., Feng, Z., Li, Q., Yi, B., & Xu, Q. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2826-x · Cited by 27
DNA demethylase Tet2 suppresses cisplatin-induced acute kidney injury
Bao, Y.-W., Bai, M., Zhu, H., Yuan, Y., Wang, Y., Zhang, Y., Wang, J., Xie, X., Yao, X., Mao, J., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00528-7 · Cited by 29
“It has also been reported that in dendritic cells and macrophages, Tet2 can suppress inflammation by recruiting histone deacetylases 2 (Hdac2) to repress IL-6 transcription specifically and downregulate other inflammatory mediators [12].”
BackgroundVitamin C for sepsis intervention: from redox biochemistry to clinical medicine
Li, Y. R., & Zhu, H. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04240-z · Cited by 30
Nowakowska, M. K., Kim, T., Thompson, M. T., Bolton, K. L., Deswal, A., Lin, S. H., Scheet, P. A., Wehner, M. R., & Nead, K. T. (2022) · American Journal of Hematology · doi:10.1002/ajh.26465 · Cited by 32
“RNA sequencing of cells bearing inactivating TET2 mutations, one of the most commonly implicated genes in CH, shows increased expression of pro-inflammatory mediators implicated in the pathogenesis of atherosclerosis, such as interleukin-1-beta (IL-1β) and interleukin-6 (IL-6).(12,42) IL-1β has been shown to mediate C…”
BackgroundTET3 epigenetically controls feeding and stress response behaviors via AGRP neurons
Xie, D., Stutz, B., Li, F., Chen, F., Lv, H., Šestan-Peša, M., Catarino, J. D. S., Gu, J., Zhao, H., Stoddard, C. E., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci162365 · Cited by 28
TET2 is required to suppress mTORC1 signaling through urea cycle with therapeutic potential
He, J., Lin, M., Zhang, X., Zhang, R., Tian, T., Zhou, Y., Dong, W., Yang, Y., Sun, X., Dai, Y., et al. (2023) · Cell Discovery · doi:10.1038/s41421-023-00567-7 · Cited by 27
Self-citationLactylation: From Homeostasis to Pathological Implications and Therapeutic Strategies
Chen, X., Yuan, Y., Zhou, F., Li, L., Pu, J., Zeng, Y., & Jiang, X. (2025) · MedComm · doi:10.1002/mco2.70226 · Cited by 39
Mooney, L., Goodyear, C. S., Chandra, T., Kirschner, K., Copland, M., Petrie, M. C., & Lang, N. N. (2021) · Clinical Science · doi:10.1042/cs20200306 · Cited by 33
Role of Tet2 in Regulating Adaptive and Innate Immunity
Li, J., Li, L., Sun, X., Deng, T., Huang, G., Li, X., Xie, Z., & Zhou, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.665897 · Cited by 34
“MiRNAs regulate TET expression posttranscriptionally, and miR-142-3p expression is induced in islet autoimmunity.”
BackgroundInfluentialSelf-citationThe role of TET2-mediated ROBO4 hypomethylation in the development of diabetic retinopathy
Zhao, L., Xu, H., Liu, X., Cheng, Y., & Xie, J. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04310-4 · Cited by 31
“Compared with TET2 depletion, ROBO4 depletion had a more marked protective effect on retinal vessels, which was attributed to the abnormal expression of many downstream factors induced by TET2 depletion, such as ROBO4, MMP-9 [47, 48], transforming growth factor β [49], and interleukin-6 [50], which play different role…”
BackgroundFunctions of TET Proteins in Hematopoietic Transformation
Han, J., An, J., & Ko, M. (2015) · Molecules and Cells · doi:10.14348/molcells.2015.0294 · Cited by 30
“In innate immune cells such as dendritic cells and macrophages, Tet2 was shown to repress Il6 transcription in the late phase of the lipopolysaccharide induced inflammatory response (Zhang et al., 2015).”
BackgroundGao, J., Ma, Y., Fu, H., Luo, Q., Wang, Z., Xiao, Y., Yang, H., Cui, D., & Jin, W. (2016) · Protein & Cell · doi:10.1007/s13238-016-0267-4 · Cited by 30
“TET proteins had been proved to be critical for numerous biological processes such as embryonic development, stem cell differentiation, immune regulation, and cancer formation (Tan and Shi, 2012; Xu et al., 2012; Li et al., 2015; Zhang et al., 2015; Dawlaty et al., 2013; Cimmino et al., 2015; Neri et al., 2015; Scourz…”
BackgroundInfluence of socioeconomic status on the whole blood transcriptome in African Americans
Gaye, A., Gibbons, G. H., Barry, C., Quarells, R. C., & Davis, S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187290 · Cited by 26
Dissecting TET2 Regulatory Networks in Blood Differentiation and Cancer
Lazarenkov, A., & Sardina, J. L. (2022) · Cancers · doi:10.3390/cancers14030830 · Cited by 29
“Moreover, inflammation-based preleukemic myeloproliferation has been linked to TET2 activity [129,130], where Il6 expression might be negatively regulated by Tet2-mediated Hdac2 recruitment to its promoter [87].”
BackgroundHormone Receptor Signaling and Breast Cancer Resistance to Anti-Tumor Immunity
Moisand, A., Madéry, M., Boyer, T., Domblides, C., Blaye, C., & Larmonier, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015048 · Cited by 28
Marchetti, A., Pelusi, S., Marella, A., Malvestiti, F., Ricchiuti, A., Ronzoni, L., Lionetti, M., Moretti, V., Bugianesi, E., Miele, L., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000839 · Cited by 28
Zheng, Q., Lin, Z., Li, X., Xin, X., Wu, M., An, J., Gui, X., Li, T., Pu, H., Li, H., et al. (2016) · Scientific Reports · doi:10.1038/srep36843 · Cited by 26
“FTO gene encods an N(6)-methyladenosine (m(6)A) RNA demethylase.”
BackgroundInfluentialSelf-citationThe Role of Somatic Mutations in Acute Myeloid Leukemia Pathogenesis
Kishtagari, A., & Levine, R. L. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034975 · Cited by 32
“Increased production of inflammatory mediators (IL-6) and bacterial translocation across gut mucosa may enhance leukemogenesis in Tet2 mice (Zhang et al. 2015; Meisel et al. 2018).”
BackgroundSelf-citationTET2 mutation as prototypic clonal hematopoiesis lesion
Guarnera, L., & Jha, B. K. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.01.013 · Cited by 29
Lian, B. S. X., Kawasaki, T., Kano, N., Ori, D., Ikegawa, M., Isotani, A., & Kawai, T. (2022) · iScience · doi:10.1016/j.isci.2022.104118 · Cited by 25
“A vital role has also been demonstrated for TET2 in suppressing inflammation during bacterial lipopolysaccharide (LPS) stimulation in innate immune cells by recruiting HDAC2 to suppress Il6 expression (Zhang et al., 2015; Cull et al., 2017).”
BackgroundLoss of TET2 impairs endothelial angiogenesis via downregulating STAT3 target genes
Shi, Y., Li, B., Huang, X., Kou, W., Zhai, M., Zeng, Y., You, S., Yu, Q., Zhao, Y., Zhuang, J., et al. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-00960-5 · Cited by 25
“It lacks a CXXC DNA binding domain and needs a co-factor for binding to DNA, especially transcription factor [33, 34].”
BackgroundTall, A. R., & Levine, R. L. (2017) · Nature · doi:10.1038/nature21505 · Cited by 25
Self-citationSun, L., Lu, S., Bai, M., Xiang, L., Li, J., Jia, C., & Jiang, H. (2019) · DNA and Cell Biology · doi:10.1089/dna.2018.4408 · Cited by 27
“Various regulatory factors control key gene expression, including transcriptional factors, epigenetic factors, and post-transcriptional factors (Zhang et al. , 2015). miRNAs play an important regulatory role, mainly through the post-transcriptional binding of target gene 3 ¢ untranslated region…”
Sun, P., Zhang, S., Maksim, S., Yao, Y., Liu, H., & Du, J. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190619143706 · Cited by 24
Sevin, M., Debeurme, F., Laplane, L., Badel, S., Morabito, M., Newman, H., Torres‐Martín, M., Yang, Q., Badaoui, B., Wagner‐Ballon, O., et al. (2021) · Blood · doi:10.1182/blood.2020008729 · Cited by 29
Matatall, K. A., Wathan, T. K., Nguyen, M., Chen, H., McDonald, A., Qi, G., Belk, J. A., Florez, M. A., Le, D. T., Olarinde, T., et al. (2025) · Cell Stem Cell · doi:10.1016/j.stem.2025.06.006 · Cited by 23
CHIP: a clonal odyssey of the bone marrow niche
Schleicher, W. E., Hoag, B., Dominici, M. D., DeGregori, J. V., & Pietras, E. M. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180068 · Cited by 24
“Conversely, dietary restriction can normalize some aging-associated HSC phenotypes, such as increased leukocyte number, myeloid lineage bias, and decreased quiescence due to suppression of IGF1 and IL-6 signaling (120, 121).”
BackgroundInfluentialIsmail, W. M., Fernandez, J. A., Binder, M., Lasho, T. L., Kim, M., Geyer, S. M., Mazzone, A., Finke, C. M., Mangaonkar, A. A., Lee, J., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014467 · Cited by 26
Liu, K., Li, Y., Shen, M., Xu, W., Wu, S., Yang, X., Zhang, B., & Lin, N. (2025) · Biomolecules · doi:10.3390/biom15010071 · Cited by 28
Rosenberg, T., Kisliouk, T., Cramer, T., Shinder, D., Druyan, S., & Meiri, N. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00767 · Cited by 24
“, 2018), others report TET-dependent reduction of inflammation and inflammatory cytokine expression via demethylation or histone deacetylation (Zhang et al., 2015; Chen et al., 2017; Hassan et al., 2018).”
BackgroundStructure and Function of TET Enzymes
Yin, X., Hu, L., & Xu, Y. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-11454-0_10 · Cited by 25
TET2–STAT3–CXCL5 nexus promotes neutrophil lipid transfer to fuel lung adeno-to-squamous transition
Xue, Y., Chen, Y., Sun, S., Tong, X., Chen, Y., Tang, S., Wang, X., Bi, S., Qiu, Y., Zhao, Q., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20240111 · Cited by 29
Schagdarsurengin, U., Teuchert, L. M., Hagenkötter, C., Nesheim, N., Dansranjavin, T., Schuppe, H., Gies, S., Pilatz, A. M. E., Weidner, W., & Wagenlehner, F. (2016) · Urologia Internationalis · doi:10.1159/000452251 · Cited by 24
Glycolipid iGb3 feedback amplifies innate immune responses via CD1d reverse signaling
Liu, X., Zhang, P., Zhang, Y., Wang, Z., Xu, S., Li, Y., Huai, W., Zhou, Q., Chen, X. '., Chen, X., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0122-7 · Cited by 23
Self-citationOlofsen, P. A., Fátrai, S., van Strien, P. M. H., Obenauer, J. C., de Looper, H. W. J., Hoogenboezem, R. M., Erpelinck-Verschueren, C. A. J., Vermeulen, M., Roovers, O., Haferlach, T., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100074 · Cited by 25
“The effects of TET2 on repressing inflammation have been assigned to its methylcytosine dioxygenase activity but also to its ability to recruit histone deacetylase (HDAC)-mediated repressor activity to pro-inflammatory genes.(17,19) To investigate whether the Cxxc4-ITD and subsequent reduction in TET2 levels altered t…”
BackgroundPomalidomide in myeloproliferative neoplasm-associated myelofibrosis
Schlenk, R. F., Stegelmann, F., Reiter, A., Jost, E., Gattermann, N., Hebart, H. F., Waller, C. F., Hochhaus, A., Platzbecker, U., Schafhausen, P., et al. (2016) · Leukemia · doi:10.1038/leu.2016.299 · Cited by 25
Clonal hematopoiesis and autoimmunity
Kishtagari, A., Corty, R. W., & Visconte, V. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.01.012 · Cited by 23
Repression of the expression of TET2 by ZEB1 contributes to invasion and growth in glioma cells
Chen, B., Lei, Y.-Q., Wang, H., Dang, Y., Fang, P., Wang, J., Yang, J., & Liu, L. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6288 · Cited by 24
“The roles of TET proteins in regulating chromatin architecture and gene transcription independently of DNA methylation have been gradually uncovered (8,26).”
BackgroundMatt, S. M., Zimmerman, J. D., Lawson, M. A., Bustamante, A. C., Uddin, M., & Johnson, R. W. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00636 · Cited by 23
Immune Dysregulation in HFpEF: A Target for Mesenchymal Stem/Stromal Cell Therapy
Sava, R., Pepine, C. J., & March, K. L. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010241 · Cited by 23
“TET2 regulates the transcription of pro-inflammatory factors such as IL-6 by binding to their gene promoters; once bound, TET2 recruits histone deacetylase (HDAC2) at this level, thereby facilitating histone deacetylation that terminates gene transcription [54].”
BackgroundTargeting Epigenetic Mechanisms in Vascular Aging
Lin, Z., Ding, Q., Li, X., Feng, Y., He, H., Huang, C., & Zhu, Y. Z. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.806988 · Cited by 24
Self-citationKAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer
Zhan, Z., Zhang, J., Liang, H., Wang, C., Li, H., & Liu, W. M. (2024) · Advanced Science · doi:10.1002/advs.202400140 · Cited by 24
Self-citationRandhawa, J., & Pålsson‐McDermott, E. M. (2025) · Journal of Inflammation · doi:10.1186/s12950-025-00461-x · Cited by 25
“On the other hand, anti-inflammatory roles include TET2 regulation of the repression of inflammatory gene transcription, including IL-6 and IL-1β [32, 33].”
Guo, X., Liu, H. N., Song, Y., Wang, J., Liu, D., Zheng, Z., Li, J., Li, B., Song, A., He, W., et al. (2026) · MedComm · doi:10.1002/mco2.70497 · Cited by 30
Zhang, K., Hussain, T. A., Wang, J., Li, M., Wang, W., Ma, X., Liao, Y., Yao, J., Song, Y., Liang, Z., et al. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00433 · Cited by 21
“By regulating the acetylation of histones, HDAC can regulate the expression of various gene and key biological process, including gene responsible for the production of inflammatory cytokines and its signaling pathways (Zhang et al., 2015).”
BackgroundGreen, H. L. H., & Brewer, A. C. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00848-y · Cited by 22
Myelodysplastic Syndromes and Metabolism
Balaian, E., Wobus, M., Bornhäuser, M., Chavakis, T., & Sockel, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011250 · Cited by 24
“Through paracrine secretion of cytokines and growth factors (such as G-CSF, IFNs, IL-6, IL-1, TGFβ, and TNFα), as well as direct interactions between niche cells and HSCs, the BM niche promotes the exit of HSCs from a quiescent state so that they can expand and differentiate into mature myeloid cells [12,67].”
BackgroundInfluentialClonal hematopoiesis is not significantly associated with COVID-19 disease severity
Zhou, Y., Shalhoub, R. N., Rogers, S. N., Yu, S. J., Gu, M., Fabre, M. A., Quirós, P. M., Shin, T., Diangson, A., Deng, W., et al. (2022) · Blood · doi:10.1182/blood.2022015721 · Cited by 23
Mechanisms of Post-critical Illness Cardiovascular Disease
Owen, A., Patel, J. M., Parekh, D., & Bangash, M. N. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.854421 · Cited by 23
“Considering that Tet2 is required for IL-6 driven inflammation repression whereas Dnmt3a represses mast cell inflammatory responses (284, 285), if treatment responders in CANTOS had a high incidence of CHIP while the treatment non-responders didn’t, a mechanistic pathway with supportive data exits to explain this obse…”
BackgroundLi, Y., Song, R., Shen, G., Huang, L., Xiao, D., Ma, Q., & Zhang, L. (2023) · Stroke · doi:10.1161/strokeaha.122.041651 · Cited by 23
Epigenetic Control of Innate Immunity: Consequences of Acute Respiratory Virus Infection
Lefkowitz, R. B., Miller, C. M., Martinez-Caballero, J. D., & Ramos, I. (2024) · Viruses · doi:10.3390/v16020197 · Cited by 25
“In addition to modulating cytokine expression through active demethylation, TET2 also represses IL-6 through the recruitment of the histone deacetylase HDAC2 in innate myeloid cells [31].”
BackgroundYang, G., Zeng, X. G., Wang, M., & Wu, A. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.01.011 · Cited by 21
Chromatin Architecture as an Essential Determinant of Dendritic Cell Function
Boukhaled, G. M., Corrado, M., Guak, H., & Krawczyk, C. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01119 · Cited by 25
GATA‐3 in T‐cell lymphoproliferative disorders
Murga‐Zamalloa, C., & Wilcox, R. A. (2019) · IUBMB Life · doi:10.1002/iub.2130 · Cited by 26
Tet Proteins Regulate Neutrophil Granulation in Zebrafish through Demethylation of socs3b mRNA
Banks, K. M., Lan, Y., & Evans, T. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108632 · Cited by 21
“Knockout of murine Tet1, Tet2, and Tet3 has demonstrated their importance in normal hematopoiesis across numerous lineages (Ichiyama et al., 2015; Langlois et al., 2014; Li et al., 2015; Lio et al., 2016; Montagner et al., 2016; Tsagaratou et al., 2017; Zhang et al., 2015).”
Renneville, A., Patnaik, M. M., Chan, O., Padron, E., & Solary, É. (2021) · Leukemia · doi:10.1038/s41375-021-01330-1 · Cited by 21
Metadata
- Authors
- Zhang, Q., Zhao, K., Shen, Q., Han, Y., Gu, Y., Li, X., Zhao, D., Liu, Y., Wang, C., Zhang, X., Su, X., Liu, J., Ge, W., Levine, R. L., Li, N., & Cao, X.
- Affiliations
- Second Military Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Cao, Xuetao
- ORCID
- Venue
- Nature
- Published
- 2015-08-19
- Volume
- 525
- Issue
- 7569
- Pages
- 389-393
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4697747
- OpenAlex
- W1171241794
- Cited by
- 807
- References
- 30
- Citations by year
- 2026: 56 · 2025: 77 · 2024: 83 · 2023: 89 · 2022: 93 · 2021: 82 · 2020: 79 · 2019: 85 · 2018: 62 · 2017: 50 · 2016: 43 · 2015: 7
- FWCI
- 23.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA173636, P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- TET2, HDAC2, interleukin-6, inflammation resolution, histone deacetylation, transcriptional repression, 5-hydroxymethylcytosine, IκB, lipopolysaccharide, dendritic cells, macrophages, endotoxic shock, DSS-induced colitis
- MeSH terms
- Interleukin-6 Inhibitors, Acetylation, Animals, Chromatin, Colitis, Dendritic Cells, DNA-Binding Proteins, Female, Histones, Humans, Inflammation, Macrophages, Male, Mice, Inbred C57BL, Promoter Regions, Genetic, Proto-Oncogene Proteins, Transcription, Genetic, Down-Regulation, Interleukin-6, DNA Methylation, I-kappa B Proteins, Epigenesis, Genetic, Dioxygenases, Mice, Histone Deacetylase 2, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.